Sponsors

Three-day service for fungal pneumonia

Lab21 is expanding its clinical diagnostics portfolio with the introduction of a new service to identify the two most common causes of fungal pneumonia. The CE-marked FXGTM:RESP (ASP+) test, developed by UK diagnostics company Myconostica, will identify infections caused by Aspergillus and Pneumocystis, which account for over 95% of cases of fungal pneumonia and could radically alter the diagnosis of fungal disease.

Fungal pneumonia is the leading cause of death due to infectious diseases in leukaemia and bone marrow transplant patients and is the most common first manifestation of acquired immune deficiency syndrome (AIDS). Accurate diagnosis of fungal pneumonia followed by appropriate antifungal treatment within the first 10 days of infection reduces the mortality rate from 90% to 40%.

www.lab21.com

Latest Issues

37th European Congress of Pathology

ACV, Vienna, Austria
6 -10 September, 2025

IBMS Congress

The International Convention Centre (ICC), Birmingham
22-25 September, 2025

Diagnostics North East Conference 2025

The Catalyst, Newcastle
3 October

Delivering POCT: Diagnostics in the Community

Manchester Conference Centre
8 October